Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery

October 28, 2026 updated by: Biyu Shen, Shanghai Jiao Tong University School of Medicine

Effects of Starry-Sky Projection and Maternal Voice on Postoperative Sleep in Children Undergoing Cardiac Surgery: A 2 × 2 Factorial Randomized Controlled Trial

The goal of this clinical trial is to determine whether a starry-sky projection affects sleep during the early period after cardiac surgery in young children. The main question it aims to answer is:

• Does a starry-sky projection improve how well children sleep during the first three nights after surgery compared with routine nighttime lighting? The study will also explore whether sleep outcomes differ between children who listen to their mother's recorded voice and those who listen to an unfamiliar woman's recorded voice, and whether the effect of the starry-sky projection differs depending on the type of voice.

Children aged 6 months to 6 years will be randomly assigned to one of four combinations of visual and sound conditions. They will:

  • Receive either a starry-sky projection or routine nighttime lighting
  • Listen to either their mother's recorded voice or an unfamiliar woman's recorded voice
  • Have their sleep monitored during the first three nights after surgery using a contactless device placed under the pillow that does not require sensors attached to the child.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

172

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200127
        • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 6 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • A confirmed diagnosis of congenital heart disease.
  • Age between 6 months and 6 years.
  • Scheduled to undergo their first elective open-heart surgery.
  • An anticipated postoperative stay in the cardiac intensive care unit (CICU) of at least 48 hours.
  • Written informed consent provided by a parent or legal guardian.

Exclusion Criteria:

  • Epilepsy or another severe neurological disorder.
  • A severe psychiatric disorder.
  • Hearing impairment that interferes with the perception of auditory stimuli.
  • Visual impairment that interferes with the perception of visual stimuli.
  • Malformations of other organs or pre-existing severe comorbidities.
  • A history of chronic pain.
  • A previously diagnosed sleep disorder.
  • Endotracheal tube could not be successfully removed before 7 p.m. on the day of surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Starry-Sky Projection + Maternal Voice

A starry-sky projector will display gently moving, diffuse star-like points on the ceiling, avoiding direct light exposure to the child's eyes. Settings will remain constant, without rapid movement, frequent colour changes, or visible flicker. Built-in audio will be disabled. Sessions will last 30 minutes before anticipated sleep onset on postoperative nights 0-2.

A personalised recording from the child's mother containing the child's name, reassuring and sleep-related phrases, and a familiar lullaby or gentle melody will be played for 30 minutes before anticipated sleep onset. The recording will be played using a speaker positioned approximately 20 cm from the child's ear, with sound intensity maintained at 45-50 dB.

Experimental: Starry-Sky Projection + Unfamiliar Female Voice

A starry-sky projector will display gently moving, diffuse star-like points on the ceiling, avoiding direct light exposure to the child's eyes. Settings will remain constant, without rapid movement, frequent colour changes, or visible flicker. Built-in audio will be disabled. Sessions will last 30 minutes before anticipated sleep onset on postoperative nights 0-2.

A standardized recording by an unfamiliar adult woman who is not involved in the child's clinical care will be played for 30 minutes before anticipated sleep onset. The recording will contain generic reassuring and sleep-related phrases and a gentle lullaby or nursery rhyme. Playback duration, speaker placement, and sound intensity will be identical to the maternal voice condition.

Active Comparator: Conventional Lighting + Maternal Voice

A personalised recording from the child's mother containing the child's name, reassuring and sleep-related phrases, and a familiar lullaby or gentle melody will be played for 30 minutes before anticipated sleep onset. The recording will be played using a speaker positioned approximately 20 cm from the child's ear, with sound intensity maintained at 45-50 dB.

Participants will remain under routine nocturnal lighting in the CICU or general ward without additional projection.

Active Comparator: Conventional Lighting + Unfamiliar Female Voice

A standardized recording by an unfamiliar adult woman who is not involved in the child's clinical care will be played for 30 minutes before anticipated sleep onset. The recording will contain generic reassuring and sleep-related phrases and a gentle lullaby or nursery rhyme. Playback duration, speaker placement, and sound intensity will be identical to the maternal voice condition.

Participants will remain under routine nocturnal lighting in the CICU or general ward without additional projection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep Efficiency
Time Frame: Postoperative nights 0, 1, and 2

Sleep efficiency is defined as the percentage of total sleep time (TST) relative to time in bed (TIB) during the sleep-related nocturnal interval. TIB refers to the interval from the start of an attempt to sleep until the end of the nocturnal sleep opportunity and includes sleep onset latency and intervening wakefulness. Sleep efficiency will be assessed using a contactless ballistocardiography (BCG)-based sleep monitoring mat during postoperative nights 0-2. The mean sleep efficiency across the three postoperative nights will be used as the primary outcome measure. Higher values indicate better sleep efficiency.

Postoperative nights 0, 1, and 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Sleep Time
Time Frame: Postoperative nights 0, 1, and 2

Total sleep time during the nocturnal monitoring period, measured using a contactless sleep monitoring mat.

Postoperative nights 0, 1, and 2
Sleep-Onset Latency
Time Frame: Postoperative nights 0, 1, and 2

Time from the beginning of the nocturnal sleep monitoring period to sleep onset, measured using a contactless sleep monitoring mat.

Postoperative nights 0, 1, and 2
Wake After Sleep Onset
Time Frame: Postoperative nights 0, 1, and 2

Total duration of wakefulness occurring after sleep onset during the nocturnal monitoring period, measured using a contactless sleep monitoring mat.

Postoperative nights 0, 1, and 2
Sleep Fragmentation Index
Time Frame: Postoperative nights 0, 1, and 2

Sleep fragmentation index derived from the contactless sleep monitoring mat, reflecting the degree of sleep disruption during the nocturnal monitoring period.

Postoperative nights 0, 1, and 2
Sleep-Stage Distribution
Time Frame: Postoperative nights 0, 1, and 2

Estimated distribution of sleep stages during the nocturnal monitoring period, expressed as the proportion of total sleep time and measured using a contactless sleep monitoring mat.

Postoperative nights 0, 1, and 2
Incidence of Postoperative Delirium
Time Frame: Postoperative night 0 through postoperative day 2

Postoperative delirium will be assessed using the Cornell Assessment of Pediatric Delirium (CAPD). A total CAPD score ≥9 will indicate a positive delirium screen. Assessments will be performed every 12 hours.

Postoperative night 0 through postoperative day 2
Richmond Agitation-Sedation Scale Score
Time Frame: Postoperative night 0 through postoperative day 2

Sedation and agitation will be assessed using the Richmond Agitation-Sedation Scale (RASS). Scores range from -5 to +4, with lower scores indicating deeper sedation and higher scores indicating greater agitation. Assessments will be performed every 4 hours.

Postoperative night 0 through postoperative day 2
Pain Score
Time Frame: Postoperative night 0 through postoperative day 2

Postoperative pain will be assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. Scores range from 0 to 10, with higher scores indicating greater pain severity. Assessments will be performed every 4 hours.

Postoperative night 0 through postoperative day 2
Postoperative Sedative Exposure
Time Frame: Postoperative day 0 through postoperative day 2

Administration of dexmedetomidine and other sedative medications will be recorded to characterize postoperative sedative exposure.

Postoperative day 0 through postoperative day 2
Postoperative Analgesic Exposure
Time Frame: Postoperative day 0 through postoperative day 2

Administration of sufentanil and other analgesic medications will be recorded to characterize postoperative analgesic exposure.

Postoperative day 0 through postoperative day 2
Postoperative Vasoactive Medication Exposure
Time Frame: Postoperative day 0 through postoperative day 2

Administration of dopamine and other vasoactive medications will be recorded to characterize postoperative vasoactive medication exposure.

Postoperative day 0 through postoperative day 2
Heart Rate Variability
Time Frame: Postoperative nights 0, 1, and 2

Heart rate variability will be continuously measured using the 5S Sleep Tracking Mat as an objective indicator of autonomic regulation.

Postoperative nights 0, 1, and 2
CICU Length of Stay
Time Frame: Measured in days admitted to the CICU, an average of 2 days

Cardiac intensive care unit (CICU) length of stay will be calculated from postoperative CICU admission to CICU discharge.

Measured in days admitted to the CICU, an average of 2 days
Total Hospital Length of Stay
Time Frame: Measured in days admitted to the hospital, an average of 10 days.

Total hospital length of stay will be calculated as the number of days from hospital admission to hospital discharge.

Measured in days admitted to the hospital, an average of 10 days.
Parental satisfaction
Time Frame: On the day of discharge, an average of 10 days

Parental satisfaction with the child's overall hospital care will be assessed using a 100-mm visual analogue scale (VAS), ranging from 0 mm ("very dissatisfied") to 100 mm ("very satisfied"). Higher scores indicate greater satisfaction.

On the day of discharge, an average of 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

September 22, 2026

First Submitted That Met QC Criteria

September 26, 2026

First Posted (Actual)

October 2, 2026

Study Record Updates

Last Update Posted (Actual)

October 30, 2026

Last Update Submitted That Met QC Criteria

October 28, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe